DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Introduction: Single-agent belantamab mafodotin (belamaf), a B-cell maturation antigen-targeting antibody-drug conjugate, achieved durable responses with a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) in the Phase 2 DREAMM-2 trial (NCT03525678). The DREAMM-5 platform trial (208887; NCT04126200) is evaluating belamaf as combination therapy with other anticancer agents to determine if belamaf's unique multimodal mechanism of action (MoA) is synergistic with MoAs of selected agents to further augment efficacy in RRMM. In this substudy, belamaf is combined with feladilimab (GSK3359609), an inducible co-stimulatory T-cell molecule (ICOS, CD278) agonist (aICOS).